CGM for Insulin-Treated T2DM During Post-Discharge Transition
NCT: NCT07414277 · NOT_YET_RECRUITING
Brief Summary
The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period. A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.
Frequently Asked Questions
What is CGM for Insulin-Treated T2DM During Post-Discharge Transition?
CGM for Insulin-Treated T2DM During Post-Discharge Transition is a clinical trial registered under NCT07414277. Current status: NOT_YET_RECRUITING.
What is the status of NCT07414277?
The current status of NCT07414277 (CGM for Insulin-Treated T2DM During Post-Discharge Transition) is: NOT_YET_RECRUITING.
When did CGM for Insulin-Treated T2DM During Post-Discharge Transition start?
CGM for Insulin-Treated T2DM During Post-Discharge Transition started on 2026-05-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.